Doctors at University of California San Francisco (UCSF) are conducting the first-of-its-kind e-NET study to learn about symptoms and quality of life for patients with neuroendocrine cancer. This is your chance to become a citizen scientist and help the researchers learn more about NETs.

A Family Takes Steps to Honor the Memory of their Loved One Judith Jones loved Nantucket. From the first time she visited the island off

Cyclebar Hilltop riders rally to support one of their instructors in her NET journey, and raise funds for NETRF research.

The American Association for Cancer Research recently recognized the NETRF-funded research of Ali Azhdarinia, PhD, of the University of Texas Health Science Center at Houston. Dr. Azhdarinia is investigating image-guided precision medicine to treat NETs in the gastrointestinal tract and pancreas that are resistant to chemotherapy.

The Neuroendocrine Tumor Research Foundation (NETRF) is pleased to welcome Dr. Matthew H. Kulke and Dr. Daniel M. Halperin to its Board of Scientific Advisors (BOSA), a volunteer council of highly distinguished medical and research leaders who share NETRF’s commitment to advancing the understanding, diagnosis, and treatment of neuroendocrine cancer. Although these renowned physicians may be new to the BOSA, they are not new to NETs or NETRF. In fact, they are both recognized as leading experts worldwide for their care of NET patients and research.

If you could ask Brandon Raabe what a perfect day would look like, he would probably describe a Sunday afternoon in a brewery surrounded by

The Neuroendocrine Tumor Research Foundation (NETRF) is pleased to collaborate with the International Neuroendocrine Cancer Alliance (INCA) to share the results from the Survey of

Update February 2024: Click here to read a recently published commentary in the journal Cancer about NET-PRO study The Patient-Centered Outcomes Research Institute (PCORI) recently

NETRF Announces Leadership Changes to the Board of Scientific Advisors It is with gratitude and profound respect that The Neuroendocrine Tumor Research Foundation (NETRF) announces